Trials / Recruiting
RecruitingNCT07275736
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
An Exploratory Clinical Study on the Safety and Efficacy of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Juventas Cell Therapy Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CNCT19 cell injection | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2027-06-01
- Completion
- 2029-06-01
- First posted
- 2025-12-10
- Last updated
- 2026-03-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07275736. Inclusion in this directory is not an endorsement.